Ebdarokimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Ebdarokimab
- ak 101
- AK-101
- ak101
- Ak101
- AK101
- ak101 iv
- AK101 IV
- ebdarokimab
- Ebdarokimab
- ebdarokimab [INN]
- Ebdarokimab [WHO-DD]
- ebdarokimab inn
- ebdarokimab who dd
- immunoglobulin g1 anti human interleukin 12 subunit beta human monoclonal ak101 gamma 1 chain disulfide with human monoclonal ak101 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 12 SUBUNIT .BETA.) (HUMAN MONOCLONAL AK101 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AK101 .KAPPA.-CHAIN, DIMER
- CAS registry numbers
- 2393651-11-9
- ChEMBL ID
- CHEMBL4650437
- FDA ingredient codes (UNII)
- PG97J3111A
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ebdarokimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- IL-12B
- Gene symbol
- IL-12B
- Mechanism
- Interleukin-12 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-12
- Protein identifier
- P29459
- Mechanism
- Interleukin-12 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-12
- Protein identifier
- P29460
- Mechanism
- Interleukin-23 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-23
- Protein identifier
- P29460
- Mechanism
- Interleukin-23 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-23
- Protein identifier
- Q9NPF7
- Mechanism
- Interleukin-12 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-12
- Mechanism
- Interleukin-23 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-23
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001494
- Subject identifier
- D011565
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 1
- NCT04172233
- NCT04173637
- NCT05120297
- NCT05509361
- NCT06281704
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (5)
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
- A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
In development for (3)
- Palmoplantar pustulosis Phase 3
- Psoriasis Phase 3
- Ulcerative colitis Phase 1